参考文献
1.Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002 May 30; 346(22): 1699–705.
2.Balzar S, Chu HW, Strand M, Wenzel S. Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am J Respir Crit Care Med. 2005 Mar 1;171(5): 431–9.
3.Carroll NG, Mutavdzic S, James AL. Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J. 2002 May; 19(5): 879–85.
4.Yu M, Tsai M, Tam SY, Jones C, Zehnder J, Galli SJ. Mast cells can promote the development of multiple features of chronic asthma in mice. J Clin Invest. 2006 Jun; 116(6): 1633–41.
5.Bradding P, Arthur G. Mast cells in asthma: state of the art. Clin Exp Allergy. 2016 Feb; 46(2): 194–263.
6.Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008 Jul 24; 454(7203): 445–54.
7.Busse W, Corren J, Lanier BQ, McAlary M,Fowler-Taylor A, Cioppa GD, et al.Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108(2): 184.
8.Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol. 2003 Jul; 112(1): 15–22.
9.Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004 Nov 18; 351(21): 2203–17.
10.Polosa R. Critical appraisal of antileukotriene use in asthma management. Curr Opin Pulm Med. 2007 Jan; 13(1): 24–30.
11.Kao CC, Parulekar AD. Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date. J Asthma Allergy. 2019; 12: 1–5.
12.Deeks ED. Dupilumab: a review in moderate to severe asthma. Drugs. 2019 Nov; 79(17): 1885–95.
13.Ribatti,D.(2016)Thedevelopmentofhuman mast cells. Anhistorical reappraisal.Exp. Cell Res.342, 210–215
14.Djukanovic R, Homeyard S, Gratziou C, Madden J, Walls A, Montefort S, et al. The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Am J Respir Crit Care Med. 1997 Mar;155(3): 826–32;
15.Tsai M, Shih LS, Newlands GF, Takeishi T, Langley KE, Zsebo KM, et al. The rat c-kit ligand, stem cell factor, induces the develop-ment of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomicaldistribution, histochemistry, and protease phenotype. J Exp Med. 1991 Jul 1; 174(1): 125–31.
16.Vliagoftis H, Worobec AS Metcalfe DD. The protooncogene c-kit and c-kit ligand in human disease. J Allergy Clin Immunol. 1997 Oct; 100(4): 435-40.
17.Paivandy A, Calounova G, Zarnegar B, Ohrvik H, Melo FR, Pejler G. Mefloquine, an anti-malaria agent, causes reactive oxygen species-dependent cell death in mast cells via a secretory granule-mediated pathway. Pharmacol Res Perspect. 2014 Dec; 2(6): e00066.)